eligibility_summary
Eligible: adults (≥18) with histologically confirmed CRC post R0 resection (stage II–IV), completed adjuvant therapy, ctDNA‑positive MRD, HLA‑A2+, no radiographic disease, adequate performance, women: negative pregnancy test + contraception, able to comply. Exclude: recent RT/chemo, steroids >2 mg/d dexamethasone, persistent ≥G2 tox, prior PD‑1/PD‑L1/CTLA‑4, abnormal labs, other active cancers, serious comorbidities/infections (incl HIV/HBV/HCV/TB), autoimmune, transplant, pregnancy/lactation, recent live vaccine, hypersensitivity, immunoactive meds, other trials.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase 2, single-arm (terminated) in ctDNA-defined minimal residual disease (MRD) colorectal cancer after curative therapy. Interventions and mechanisms: • EO2040: microbial-derived therapeutic peptide vaccine (type: peptide vaccine) containing two peptides that mimic CD8+ T-cell epitopes from tumor-associated antigens plus a CD4+ helper peptide (UCP2), emulsified with Montanide to boost antigen presentation. Mechanism: primes/expands TAA-specific cytotoxic CD8+ T cells with CD4+ T-cell help, HLA-A2–restricted. • Nivolumab: anti–PD-1 monoclonal antibody (checkpoint inhibitor) that blocks PD-1 to reverse T-cell exhaustion. Targets: CD8+ and CD4+ T cells, antigen-presenting cells/HLA-A2 pathway, and the PD-1/PD-L1 checkpoint in the tumor microenvironment.